Clinical trial
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
NCT04166409 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- January 31, 2020
- Completion date
- December 31, 2030
- Enrollment
- 170 (estimated)
- Sites
- 132
Conditions
As the registry lists them; a condition with its own page is linked.
low grade astrocytoma, low grade glioma, metastatic low grade astrocytoma, metastatic low grade glioma, who grade 1 glioma, who grade 2 glioma